BRIEF published on 08/08/2025 at 02:20, 1 year ago CureVac Settles Patent Dispute with Pfizer/BioNTech MRNA Technology CureVac Pfizer/BioNTech Patent Resolution Vaccine Royalties
PRESS RELEASE published on 08/08/2025 at 02:15, 1 year ago CureVac Announces Resolution of Patent Litigation with Pfizer/BioNTech CureVac resolves patent litigation with Pfizer/BioNTech related to mRNA-based COVID-19 vaccines, receiving $790 million and non-exclusive license agreements BioNTech MRNA Technology CureVac Patent Litigation Pfizer
BRIEF published on 06/24/2025 at 22:14, 1 year 2 months ago CureVac publie les résultats de son assemblée générale annuelle CureVac Nominations Au Conseil D'administration Commissaires Aux Comptes Technologie De L'ARNm Assemblée Annuelle
BRIEF published on 06/24/2025 at 22:14, 1 year 2 months ago CureVac Reports Outcomes of Annual General Meeting MRNA Technology Annual Meeting Board Appointments Auditors CureVac
PRESS RELEASE published on 06/24/2025 at 22:09, 1 year 2 months ago CureVac Announces Voting Results of General Meeting CureVac announces voting results of Annual General Meeting, including new Management Board and Supervisory Board appointments. KPMG reappointed as external auditors Annual General Meeting Appointments Voting Results KPMG CureVac
BRIEF published on 05/20/2025 at 13:05, 1 year 3 months ago CureVac Reports Q1 2025 Financials and Business Developments Financial Results Revenue Patents Oncology Pipeline R&D Developments
BRIEF published on 05/20/2025 at 13:05, 1 year 3 months ago CureVac publie ses résultats financiers et ses développements commerciaux pour le premier trimestre 2025 Résultats Financiers Brevets Revenu Pipeline En Oncologie Développements En R&D
PRESS RELEASE published on 05/20/2025 at 13:00, 1 year 3 months ago CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates CureVac announces financial results for Q1 2025 and updates on lung cancer and glioblastoma trials, urinary tract infection vaccine, and mRNA patents. Cash position strong at €438.3 million Financial Results Oncology Pipeline CureVac Q1 2025 MRNA Patents
BRIEF published on 05/15/2025 at 22:15, 1 year 3 months ago CureVac Gains Favorable Patent Decision Against BioNTech BioNTech MRNA Technology CureVac Patent Litigation European Patent Office
BRIEF published on 05/15/2025 at 22:15, 1 year 3 months ago CureVac obtient une décision favorable en matière de brevets contre BioNTech BioNTech CureVac Technologie De L'ARNm Office Européen Des Brevets Litiges En Matière De Brevets
Published on 08/28/2026 at 08:05, 3 hours 48 minutes ago Caledonia Mining Corporation Plc: Maiden Mineral Resource Estimate at Motapa 379,000 oz Measured and Indicated; 131,000 oz Inferred
Published on 08/28/2026 at 08:05, 3 hours 48 minutes ago Tocvan Announces New Surface Mineralization in Several Zones at Gran Pilar Gold-Silver Project
Published on 08/28/2026 at 08:00, 3 hours 53 minutes ago Caledonia Mining Corporation Plc: Blanket Mine Underground Measured and Indicated Mineral Resources Estimate Increases by 22% to 2.18 Million Ounces and Declaration of a Surface Mineral Resource Estimate
Published on 08/28/2026 at 04:30, 7 hours 23 minutes ago Snipp Interactive Reports Q2 2026 Financial Results; Returns to Positive EBITDA on Highest Quarterly Revenue in Five Quarters
Published on 08/27/2026 at 23:05, 12 hours 48 minutes ago Galway Metals Announces Filing of NI 43-101 Technical Report for Updated Clarence Stream Mineral Resource Estimate
Published on 08/28/2026 at 11:15, 38 minutes ago Redcare Pharmacy announces Managing Board succession: Peter Schmid von Linstow to succeed Olaf Heinrich as part of a planned leadership transition.
Published on 08/28/2026 at 11:12, 40 minutes ago EQS-Adhoc: Redcare Pharmacy N.V.: Change in the Managing Board; Peter Schmid von Linstow to become Chief Executive Officer.
Published on 08/28/2026 at 11:00, 53 minutes ago Warren Wise Unravels the Rheinmetall Paradox – Defense Boom Without a Share Price Rally
Published on 08/28/2026 at 10:58, 55 minutes ago High approval at the Annual General Meeting – Shareholders confirm the course of Netfonds AG
Published on 08/26/2026 at 18:02, 1 day 17 hours ago Altareit: Altarea press release regarding the Primonial matter
Published on 08/26/2026 at 18:02, 1 day 17 hours ago Altareit : Communiqué de presse d’Altarea relatif au dossier Primonial
Published on 08/26/2026 at 18:00, 1 day 17 hours ago Altarea: Comprehensive settlement agreement reached, ending the dispute between Altarea and the shareholders of the Praemia group (formerly Primonial group)
